Denali Capital Acquisition Corp’s shareholders have approved the merger with Semnur Pharmaceuticals, clearing the way for Semnur—a majority-owned subsidiary of Scilex Holding Company—to go public via SPAC. The combined company is slated to operate as Semnur Pharmaceuticals upon closing, expected this month, positioning its late-stage, non-opioid epidural gel, SP-102 (Semdexa), as the lead value driver. The deal also implicitly links Semnur to Scilex’s commercial footprint across non-opioid pain brands, creating potential launch synergies if SP-102 advances to market.
The strategic bet is clear: use the SPAC route to capitalize on a single-asset, late-stage pain platform at a time when traditional crossover rounds remain tight and IPO windows are selective. For Scilex, externalizing Semnur provides a cleaner capital story around a procedure-anchored asset while retaining strategic influence. The open question is whether this structure delivers sufficient, durable cash post-redemptions to fund regulatory milestones, a procedure-focused launch, and the evidence generation payers will demand.
Why this matters now is the convergence of three forces reshaping pain therapeutics. First, payers remain intent on curbing opioid use, yet demand hard comparative value for premium non-opioid options. Second, the standard of care for lumbosacral radicular pain still leans on generic steroid injections with mixed, operator-dependent outcomes. Third, procedural drugs straddle medical-benefit economics that can accelerate adoption if coding and buy-and-bill align—or stall it if prior authorization, step edits, and site-of-care rules tighten. A proprietary dexamethasone gel designed for epidural use aims to differentiate on consistency and safety profile considerations relevant to particulate vs non-particulate steroids, but formulary traction will hinge on data that translate into fewer repeat injections, reduced downstream surgeries, and lower opioid rescue.
For Medical Affairs, this pathway is unforgiving and opportunity-rich. Success will require deep engagement with interventional pain, anesthesiology, and PM&R societies; pragmatic trials and registries that track function, return-to-work, and procedure-utilization endpoints; and robust training to standardize administration. Without head-to-heads against commonly used corticosteroids and real-world evidence in diverse sites of care—including ambulatory surgery centers—payers are likely to default to generics. Early planning for coding, a permanent J-code, and distributor and GPO alignment will be as critical as label language in shaping adoption curves.
Competitively, Semnur enters a fragmented non-opioid landscape where neuromodulation devices, generic injectables, and emerging peripherally restricted sodium channel inhibitors vie for budget and attention. The bar for differentiation is rising after years of pain, disappointments, and payer pushback on premium analgesics. Yet the market is receptive to credible opioid-sparing interventions supported by measurable utilization benefits. In parallel, the transaction underscores a broader financing trend: selective reemergence of SPACs for late-stage, revenue-adjacent assets where parent companies can contribute infrastructure while the spun-out entity becomes a focused capital vehicle. If listing proceeds are solid, Semnur could also become a consolidator of adjacent interventional pain assets or pursue ex-US partnerships to extend its runway.
Watch for three near-term signals: net cash at close after redemptions, clarity on the regulatory timetable for SP-102 following its completed Phase 3 program, and the contours of a payer-access strategy that aligns clinical claims with medical-benefit economics. The strategic question for Commercial and Medical leaders is whether a procedure-anchored, non-opioid therapy can secure premium positioning against entrenched generics—and, if it does, whether this model becomes a blueprint for bringing procedural pharmaceuticals back into favor across pain and beyond.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
